CAPS Medical
- Industry
- Medical Devices
- Founded Year
- 2018
- Headquarters
- Netanya, Israel
- Employee Count
- 0
Key People
- Ilan Uchitel - CEO
- Dr. Zvi Fridlender - Co-Founder & Chief Medical Officer
- Dr. Yair Lior - Co-Founder & Chief Technology Officer
Assessment
- Team
-
Aspect: First-time physician innovator
Summary: The leadership team comprises first-time entrepreneurs with significant medical and technical expertise.
While the team possesses strong medical and technical backgrounds, their lack of prior entrepreneurial experience could impact their ability to effectively manage business operations, secure funding, and scale the company. This may necessitate the inclusion of experienced business professionals or advisors to mitigate potential risks.
- Clinical Need
-
Aspect: Very Strong
Summary: There is a significant unmet need for minimally invasive and selective cancer treatments.
Current cancer treatments often involve invasive procedures and can harm healthy tissues. CAPS Medical's Cold Atmospheric Plasma technology offers a minimally invasive alternative that selectively targets cancer cells, addressing a substantial unmet need in oncology. This innovation has the potential to improve patient outcomes and reduce side effects, making it highly attractive to both patients and healthcare providers.
- Competition
-
Aspect: First mover
Summary: CAPS Medical is among the pioneers in applying Cold Atmospheric Plasma for cancer treatment.
As one of the first companies to develop Cold Atmospheric Plasma technology for cancer treatment, CAPS Medical has the opportunity to set industry standards, build strong brand recognition, and establish strategic partnerships. This first-mover advantage can lead to a dominant market position, provided the company effectively executes its commercialization strategy.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing and commercializing Cold Atmospheric Plasma technology presents moderate technical challenges.
The application of Cold Atmospheric Plasma in medical treatments involves complexities such as ensuring precise control over plasma parameters, maintaining consistent treatment outcomes, and adhering to stringent safety standards. These technical challenges necessitate rigorous research and development efforts to achieve a reliable and effective product suitable for clinical use.
- Patent
-
Aspect: Strong
Summary: The company holds strong patents protecting its Cold Atmospheric Plasma technology.
Holding strong patents ensures that CAPS Medical has exclusive rights to its technology, preventing competitors from replicating their innovations. This intellectual property protection not only secures the company's market position but also opens avenues for strategic partnerships and licensing deals, potentially generating additional revenue streams.
- Financing
-
Aspect: Medium
Summary: The company has secured moderate funding from investors like The Trendlines Group and MedTech Innovator.
While initial funding has been obtained, the development and commercialization of medical devices are capital-intensive processes. Significant resources are needed for clinical trials, regulatory approvals, manufacturing, and marketing. Therefore, securing additional financing will be crucial for CAPS Medical to successfully bring its product to market and achieve sustainable growth.
- Regulatory
-
Aspect: Running FIH
Summary: The company is currently conducting First-In-Human (FIH) trials for its technology.
Initiating First-In-Human trials indicates that CAPS Medical's technology has reached a significant milestone in its development. These trials are essential for demonstrating safety and preliminary efficacy, which are critical for obtaining regulatory approvals. Successful completion of these trials will pave the way for larger clinical studies and eventual market entry.
Opportunity Rollup
- Odds of Success
- 3.55
- Peak Market Share
- 5.05
- Segment CAGR
- 15.8%
- Market Segment
- Medical Devices
- Market Sub Segment
- Cancer Treatment Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.25 |
| 2 | 0.76 |
| 3 | 1.77 |
| 4 | 3.53 |
| 5 | 5.05 |
Key Takeaway
CAPS Medical's innovative Cold Atmospheric Plasma technology addresses a significant unmet need in cancer treatment, offering a minimally invasive alternative with potential for high market adoption. However, the company must navigate technical challenges, secure additional funding, and successfully complete clinical trials to achieve commercialization and market penetration.